Serum bilirubin ≤1.5 x Upper limit of normal (UNL) 2 mg/dl;
Prior ovarian surgery before starting study treatment;
Covered by a Healthcare System, where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research;
Signed written informed consent obtained prior to any study-specific screening procedures.
You may not be if
Platinum-refractory EOC (i.e progression under platinum containing chemotherapy);
Any prior malignancy not considered in complete remission for at least 2 years;
Pregnancy or breastfeeding;
Untreated central nervous system disease or symptomatic central nervous system metastasis, history or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment;
Uncontrolled hypertension or active clinically significant cardiovascular disease;
Females of childbearing age not using medically accepted contraceptive measures, as judged by the investigator;
Contraindication to any drug contained in the chemotherapy regimen;
Known contraindication to cisplatin
Medical, geographical, sociological, psychological or legal conditions that would prevent the patient from completing the study or signing the informed consent;
Any significant disease which, in the investigator's opinion, excludes the patient from the study;
Under any administrative or legal supervision.
Clareo Health | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
